Skip to content
Homepage
Author:
Zymeworks Inc.
Posted Date:
September 28, 2026
Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition
Zymeworks Inc.
September 28, 2026
Zymeworks Completes Acquisition of Theravance Biopharma
Zymeworks Inc.
September 23, 2026
U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
Zymeworks Inc.
August 25, 2026
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Inc.
August 11, 2026
Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Zymeworks Inc.
August 6, 2026
